KineMed is a biotechnology company specialized in translational and personalized medicine.
As per the agreement, KineMed has given license to its technologies to Bristol-Myers Squibb for identifying and characterizing biomarkers for Alzheimer’s disease in cerebrospinal fluid.
KineMed president and CEO David Fineman said KineMed is enabling research on potential treatments that address the causes, rather than the symptoms, of disease.